These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. CAPE suppresses VEGFR-2 activation, and tumor neovascularization and growth. Chung TW; Kim SJ; Choi HJ; Kwak CH; Song KH; Suh SJ; Kim KJ; Ha KT; Park YG; Chang YC; Chang HW; Lee YC; Kim CH J Mol Med (Berl); 2013 Feb; 91(2):271-82. PubMed ID: 22935775 [TBL] [Abstract][Full Text] [Related]
29. The novel VEGF receptor/MET-targeted kinase inhibitor TAS-115 has marked in vivo antitumor properties and a favorable tolerability profile. Fujita H; Miyadera K; Kato M; Fujioka Y; Ochiiwa H; Huang J; Ito K; Aoyagi Y; Takenaka T; Suzuki T; Ito S; Hashimoto A; Suefuji T; Egami K; Kazuno H; Suda Y; Nishio K; Yonekura K Mol Cancer Ther; 2013 Dec; 12(12):2685-96. PubMed ID: 24140932 [TBL] [Abstract][Full Text] [Related]
30. Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer. Taeger J; Moser C; Hellerbrand C; Mycielska ME; Glockzin G; Schlitt HJ; Geissler EK; Stoeltzing O; Lang SA Mol Cancer Ther; 2011 Nov; 10(11):2157-67. PubMed ID: 21885862 [TBL] [Abstract][Full Text] [Related]
31. KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties. Nakamura K; Taguchi E; Miura T; Yamamoto A; Takahashi K; Bichat F; Guilbaud N; Hasegawa K; Kubo K; Fujiwara Y; Suzuki R; Kubo K; Shibuya M; Isae T Cancer Res; 2006 Sep; 66(18):9134-42. PubMed ID: 16982756 [TBL] [Abstract][Full Text] [Related]
32. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Wedge SR; Ogilvie DJ; Dukes M; Kendrew J; Chester R; Jackson JA; Boffey SJ; Valentine PJ; Curwen JO; Musgrove HL; Graham GA; Hughes GD; Thomas AP; Stokes ES; Curry B; Richmond GH; Wadsworth PF; Bigley AL; Hennequin LF Cancer Res; 2002 Aug; 62(16):4645-55. PubMed ID: 12183421 [TBL] [Abstract][Full Text] [Related]
33. Antitumor vascular strategy for controlling experimental metastatic spread of human small-cell lung cancer cells with ZD6474 in natural killer cell-depleted severe combined immunodeficient mice. Yano S; Muguruma H; Matsumori Y; Goto H; Nakataki E; Edakuni N; Tomimoto H; Kakiuchi S; Yamamoto A; Uehara H; Ryan A; Sone S Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8789-98. PubMed ID: 16361567 [TBL] [Abstract][Full Text] [Related]
34. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584. Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977 [TBL] [Abstract][Full Text] [Related]
35. Multiscale modeling reveals angiogenesis-induced drug resistance in brain tumors and predicts a synergistic drug combination targeting EGFR and VEGFR pathways. Liang W; Zheng Y; Zhang J; Sun X BMC Bioinformatics; 2019 May; 20(Suppl 7):203. PubMed ID: 31074391 [TBL] [Abstract][Full Text] [Related]
36. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice. Chen Y; Ramjiawan RR; Reiberger T; Ng MR; Hato T; Huang Y; Ochiai H; Kitahara S; Unan EC; Reddy TP; Fan C; Huang P; Bardeesy N; Zhu AX; Jain RK; Duda DG Hepatology; 2015 May; 61(5):1591-602. PubMed ID: 25529917 [TBL] [Abstract][Full Text] [Related]
37. Signaling for lymphangiogenesis via VEGFR-3 is required for the early events of metastasis. Matsumoto M; Roufail S; Inder R; Caesar C; Karnezis T; Shayan R; Farnsworth RH; Sato T; Achen MG; Mann GB; Stacker SA Clin Exp Metastasis; 2013 Aug; 30(6):819-32. PubMed ID: 23591595 [TBL] [Abstract][Full Text] [Related]
38. Chidamide plus Tyrosine Kinase Inhibitor Remodel the Tumor Immune Microenvironment and Reduce Tumor Progression When Combined with Immune Checkpoint Inhibitor in Naïve and Anti-PD-1 Resistant CT26-Bearing Mice. Chen JS; Hsieh YC; Chou CH; Wu YH; Yang MH; Chu SH; Chao YS; Chen CN Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142591 [TBL] [Abstract][Full Text] [Related]
39. Suppression of prostate cancer nodal and systemic metastasis by blockade of the lymphangiogenic axis. Burton JB; Priceman SJ; Sung JL; Brakenhielm E; An DS; Pytowski B; Alitalo K; Wu L Cancer Res; 2008 Oct; 68(19):7828-37. PubMed ID: 18829538 [TBL] [Abstract][Full Text] [Related]
40. Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy. Qin S; Li A; Yi M; Yu S; Zhang M; Wu K J Hematol Oncol; 2019 Mar; 12(1):27. PubMed ID: 30866992 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]